Bortezomib liposomal - The WhiteOak Group
Alternative Names: Myzomib; WGI-0401Latest Information Update: 08 Apr 2022
At a glance
- Originator The WhiteOak Group
- Class Amides; Anti-ischaemics; Antineoplastics; Antirheumatics; Boronic acids; Pyrazines; Small molecules; Vascular disorder therapies
- Mechanism of Action Apoprotein stimulants; NF-kappa B inhibitors; Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Multiple myeloma
Most Recent Events
- 16 Mar 2022 Before March 2022 preclinical trials in Multiple myeloma in USA (IV-injection) (The WhiteOak Group pipeline , March 2022)
- 16 Mar 2022 Pharmacokinetcs data from a preclinical trial in Multiple myeloma released by The WhiteOak Group (The WhiteOak Group pipeline , March 2022)